Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Follow-up and Outcome of Operative Treatment With Decompressive Release Of The Peroneal Nerve

NCT04695834 · tracked via the Priya Life Science Belgium tracker
Phase
Not applicable
Started
2021-04-28
Last updated
2024-07-01

Condition(s) studied

Peroneal Nerve Entrapment

Investigational drug(s) / intervention(s)

Neurolysis peroneal nerveMaximal physiotherapy

Neurolysis peroneal nerve: The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa

Maximal physiotherapy: Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule

Study summary

The FOOT DROP trial is a prospective, multi-center, randomized controlled trial to assess if decompressive surgery for peroneal nerve entrapment is superior to maximal conservative treatment.

Patients with persisting foot drop due to peroneal nerve entrapment will be randomized to either surgery or conservative treatment if foot drop persists 10 +/- 4 weeks after onset of symptoms.

Patients will be evaluated through several questionnaires, evolution of muscle strength and several types of gait assessments. Primary endpoint is the difference in distance covered during the six minute walking test between baseline and 9 months after randomization.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Written informed consent to participate in the study must be obtained from the subject or proxy / legal representative prior to initiation of any study-mandated procedure * EDX-documented peroneal nerve entrapment with persisting (10 ± 4 weeks) foot drop (MRC-score ≤ 3) * Imaging (ultrasound/MRI) performed to exclude a compressive mass * Age ≥ 18 years Exclusion Criteria: * Subjects with posttraumatic or iatrogenic peroneal nerve injury * Subjects with peroneal neuropathy due to a compressive mass (e.g. cyst, tumour) * Peroneal nerve entrapment at other sites than the fibular head * Patients with mental or physical problems that incapacitate them to participate in a physiotherapy program * Psychiatric illness * Pregnancy * Planned (e)migration within 1 year after randomization to another country * Subjects with previous foot drop * Permanently bedridden subjects * Subjects with neurological or musculoskeletal history which could impact foot drop assessment and/or gait analysis (e.g. polyneuropathy, hereditary neuropathy with pressure palsies, critical illness polyneuropathy, previous stroke, ankle surgery, …).

Primary outcome measure(s)

  • The difference in distance covered in meters during the six-minute walk test (6MWD) between baseline and 9 months after randomization. — 9 months
    Based on a literature analysis and patient feedback on the trial design, gait analysis and recovery of a normal gait pattern are crucial in the recovery of foot drop. In 90% of interviewed patients, success of treatment was related to improvement in gait. The distance covered during the six-minute walk test (6MWT) is validated and clinically used in gait analysis. 6MWT: patients are instructed to walk as far as possible within six minutes (strokes of 30 meters of more). The minimal age- and sex-specific normal 6MWD is defined as 82% of the applied reference equations for prediction of the 6MWD. The reference value that will be used is 6MWDpred(m) = 868.8 - (ageyears x 2.99) - (gender x 74.7). The value for gender is 0 in male subjects and 1 in female subjects.

Trial sites (18)

FacilityCityRegionStatus
AZ Sint-Maarten Mechelen Antwerpen Not Yet Recruiting
AZ Turnhout Turnhout Antwerpen Not Yet Recruiting
Sint Augustinus Wilrijk Antwerpen Not Yet Recruiting
Jessa Ziekenhuis Hasselt Limburg Not Yet Recruiting
AZ Vesalius Tongeren Limburg Not Yet Recruiting
AZ Alma Eeklo Oost-Vlaanderen Not Yet Recruiting
AZ Sint-Lucas Ghent Oost-Vlaanderen Not Yet Recruiting
AZ Sint-Jan Bruges West-Vlaanderen Not Yet Recruiting
AZ Groeninge, department of neurosurgery Kortrijk West-Vlaanderen Recruiting
AZ Damiaan Ostend West-Vlaanderen Not Yet Recruiting
AZ Delta Roeselare West-Vlaanderen Not Yet Recruiting
Universitaire Ziekenhuizen Antwerpen Antwerp Belgium Not Yet Recruiting
ULB Erasme, department of neurosurgery Brussels Belgium Recruiting
UZ Brussel Brussels Belgium Not Yet Recruiting
Ziekenhuis Oost-Limburg, department of neurosurgery Genk Belgium Recruiting
University Hospitals Of Leuven, department of neurosurgery Leuven Belgium Recruiting
CHU de Liège, department of neurosurgery Liège Belgium Recruiting
Leids Universitair Medisch Centrum, department of neurosurgery Leiden Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04695834 on ClinicalTrials.gov ↗ ← All trials in Belgium